Infarct artery patency predicts outcome of serial electropharmacological studies in patients with malignant ventricular tachyarrhythmias. | Zendy

John T.Y. Hii | Zendy; M Traboulsi | Zendy; L. Brent Mitchell | Zendy; D. George Wyse | Zendy; Henry J. Duff | Zendy; Anne M. Gillis | Zendy

Open Access

Infarct artery patency predicts outcome of serial electropharmacological studies in patients with malignant ventricular tachyarrhythmias.

Author(s) -

John T.Y. Hii,

M Traboulsi,

L. Brent Mitchell,

D. George Wyse,

Henry J. Duff,

Anne M. Gillis

Publication year - 1993

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.87.3.764

Subject(s) - medicine , cardiology , myocardial infarction , ventricular tachycardia , drug , coronary artery disease , ventricular fibrillation , population , pharmacology , environmental health

Surviving myocardial cells near the infarct border zone form the arrhythmogenic substrate for sustained ventricular tachycardia (VT) in humans. Infarct-related artery (IRA) patency may modulate the electrophysiological function of this arrhythmogenic substrate and its response to antiarrhythmic drug therapy. We postulated that effective antiarrhythmic drug therapy selected during serial electrophysiological studies in patients with VT after a myocardial infarction would be identified more frequently when the IRA is patent than when chronically occluded.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research